Critical illness associated new onset atrial fibrillation: subsequent atrial fibrillation diagnoses and other adverse outcomes
EP Europace · 2023
DOI: 10.1093/europace/euac174 ↗Kurz gefasst
Fachartikel in der Zeitschrift EP Europace, 2023. Verfasst von Daniel Lancini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Royal Brisbane and Women's Hospital, Brisbane 4029, Australia. Hauptthemen laut MEDLINE: Atrial Fibrillation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council, the Health Innovation, Investment and Research Office.
Abstract (Originalsprache)
Aims
Amongst patients with critical illness associated new onset AF (CI-NOAF), the risk of subsequent atrial fibrillation (AF) diagnoses and other adverse outcomes is unknown, and the role for long-term anticoagulation is unclear. This study sought to determine the factors associated with subsequent AF diagnoses and other adverse outcomes in this cohort. Methods and results Admissions to a tertiary general intensive care unit (ICU) between December 2015 and September 2018 were screened for AF episodes through hourly analysis of continuous ECG monitoring. Patients with a prior history of AF were excluded. AF burden was defined as the percentage of monitored ICU hours in AF. The primary endpoint was subsequent AF diagnoses, as collated from the statewide electronic medical records. Secondary endpoints included mortality, embolic events, MACE and subsequent anticoagulation.
Results
Of 7030 admissions with 509 303 h of monitoring data, 309 patients with CI-NOAF were identified, and 235 survived to discharge. Subsequent AF diagnoses were identified in 75 (31.9%) patients after a median of 413 days. Increased AF burden had the strongest independent association with AF recurrence (OR = 15.03, P = 0.002), followed by increased left atrial area (OR = 1.12, P = 0.01). Only 128 (54.5%) patients had their AF diagnosis acknowledged at ICU discharge, and 50 (21.3%) received anticoagulation at hospital discharge.
Conclusion
CI-NOAF is often under-recognized, and subsequent AF diagnoses are common post-discharge. AF burden during ICU admission has a strong independent association with subsequent AF diagnoses. Left atrial size is also independently associated with subsequent AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, Royal Brisbane and Women's Hospital, Brisbane 4029, Australia.
- Faculty of Medicine, University of Queensland, Brisbane 4006, Australia.
- Burns, Trauma and Critical Care Research Centre, University of Queensland, Brisbane 4029, Australia.
- School of Medicine, Griffith University, Brisbane 4111, Australia.
ORCID-Profile: Daniel Lancini, Kristyan Guppy-Coles, Robert Boots, Sandhir Prasad, John Atherton, Paul Martin
Förderung
- National Health and Medical Research Council
- the Health Innovation
- Investment and Research Office
- Queensland Health
- Junior Doctor Research Fellowship
Zitieren
APA
Lancini, D., Tan, W. L., Guppy-Coles, K., Boots, R., Prasad, S., Atherton, J., & Martin, P. (2023). Critical illness associated new onset atrial fibrillation: subsequent atrial fibrillation diagnoses and other adverse outcomes. EP Europace. https://doi.org/10.1093/europace/euac174
Vancouver
Lancini D, Tan WL, Guppy-Coles K, Boots R, Prasad S, Atherton J, et al. Critical illness associated new onset atrial fibrillation: subsequent atrial fibrillation diagnoses and other adverse outcomes. EP Europace. 2023. doi:10.1093/europace/euac174
BibTeX
@article{Lancini2023,
author = {Lancini, Daniel and Tan, Wei Lian and Guppy-Coles, Kristyan and Boots, Robert and Prasad, Sandhir and Atherton, John and Martin, Paul},
title = {Critical illness associated new onset atrial fibrillation: subsequent atrial fibrillation diagnoses and other adverse outcomes},
journal = {EP Europace},
year = {2023},
doi = {10.1093/europace/euac174}
}
EUVIMED